Systemic therapy for recurrent meningioma

References

• Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009;9(3):231–240.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma. Curr Opin Oncol. 2012;24(6):666–671.
   PubMed Web of Science ®Google Scholar
• Brem SS, Bierman PJ, Brem H, et al. Central nervous system cancers. J Natl Compr Cancer Netw JNCCN. 2011;9(4):352–400.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Is there effective systemic therapy for recurrent surgery- and radiation-refractory meningioma? CNS Oncol. 2013;2(1):1–5.
   PubMedGoogle Scholar
• Domingues PH, Sousa P, Otero Á, et al. Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro-Oncol. 2014;16(5):735–747.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM. Brain tumors. N Engl J Med. 2001;344(2):114–123.
   PubMed Web of Science ®Google Scholar
• Olar A, Wani KM, Sulman EP, et al. Mitotic index is an independent predictor of recurrence-free survival in meningioma. Brain Pathol Zurich Switz. 2015;25(3):266–275.
   PubMed Web of Science ®Google Scholar
• Sahm F, Schrimpf D, Olar A, et al. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016;108(5). pii:djv377. doi:10.1093/jnci/djv377
   PubMedGoogle Scholar
• NCCN Clinical Practice Guidelines in Oncology [Internet]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#cns
   Google Scholar
• Kaley T, Barani I, Chamberlain M, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncol. 2014;16(6):829–840.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. What lessons imparted from SWOG S9005 for recurrent meningioma? J CLin Oncol. 2016. [Epub ahead of print]
   Web of Science ®Google Scholar
• Yew A, Trang A, Nagasawa DT, et al. Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas. J Clin Neurosci Off J Neurosurg Soc Australas. 2013;20(1):17–22.
   Web of Science ®Google Scholar
• Norden AD, Ligon KL, Hammond SN, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015;84(3):280–286.
   PubMed Web of Science ®Google Scholar
• Furtner J, Schöpf V, Seystahl K, et al. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-Oncol. 2016;18(3):401–407.
   PubMed Web of Science ®Google Scholar
• Preusser M, Berghoff AS, Hottinger AF. High-grade meningiomas: new avenues for drug treatment? Curr Opin Neurol. 2013;26(6):708–715.
   PubMed Web of Science ®Google Scholar
• Mawrin C, Chung C, Preusser M. Biology and clinical management challenges in meningioma. Am Soc Clin Oncol Educ Book ASCO Am Soc Clin Oncol Meet. 2015;35:e106–115.
   Google Scholar
• Kato Y, Nishihara H, Mohri H, et al. Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma. Brain Tumor Pathol. 2014;31(1):23–30.
   PubMed Web of Science ®Google Scholar
• Baumgarten P, Brokinkel B, Zinke J, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas. Histol Histopathol. 2013;28(9):1157–1166.
   PubMed Web of Science ®Google Scholar
• Wu Y, Lucia K, Lange M, et al. Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas. J Neurooncol. 2014;119(2):263–273.
   PubMed Web of Science ®Google Scholar
• Koschny R, Krupp W, Xu L-X, et al. WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma. Pathol Res Pract. 2015;211(2):109–116.
   PubMed Web of Science ®Google Scholar
• Saini M, Jha AN, Abrari A, et al. Expression of proto-oncogene KIT is up-regulated in subset of human meningiomas. BMC Cancer. 2012;12:212.
   PubMed Web of Science ®Google Scholar
• Choy W, Kim W, Nagasawa D, et al. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus. 2011;30(5):E6.
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45(3):285–289.
   PubMed Web of Science ®Google Scholar
• Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077–1080.
   PubMed Web of Science ®Google Scholar
• Abedalthagafi M, Bi WL, Aizer AA, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro-Oncol. 2016;18:649–655.
   PubMed Web of Science ®Google Scholar
• Sahm F, Bissel J, Koelsche C, et al. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol (Berl). 2013;126(5):757–762.
   PubMed Web of Science ®Google Scholar
• Van Den Munckhof P, Christiaans I, Kenter SB, et al. Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics. 2012;13(1):1–7.
   PubMed Web of Science ®Google Scholar
• Smith MJ, O’Sullivan J, Bhaskar SS, et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet. 2013;45(3):295–298.
   PubMed Web of Science ®Google Scholar
• Gutmann DH, Donahoe J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet. 2000;9(10):1495–1500.
   PubMed Web of Science ®Google Scholar
• Perry A, Cai DX, Scheithauer BW, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol. 2000;59(10):872–879.
   PubMed Web of Science ®Google Scholar
• Yun S, Koh JM, Lee KS, et al. Expression of c-MET in invasive meningioma. J Pathol Transl Med. 2015;49(1):44–51.
   PubMedGoogle Scholar
• Du Z, Abedalthagafi M, Aizer AA, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6(7):4704–4716.
   PubMed Web of Science ®Google Scholar
• Baia GS, Caballero OL, Ho JSY, et al. NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches. Cancer Immunol Res. 2013;1(5):296–302.
   PubMed Web of Science ®Google Scholar
• Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997;86(5):845–852.
   PubMed Web of Science ®Google Scholar
• Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86(5):840–844.
   PubMed Web of Science ®Google Scholar
• Mason WP, Gentili F, Macdonald DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningiomas. J Neurosurg. 2002;97(2):341–346.
   PubMed Web of Science ®Google Scholar
• Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci Off J Neurosurg Soc Australas. 2002;9(2):156–158.
   Web of Science ®Google Scholar
• Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg. 2004;18(5):495–499.
   PubMed Web of Science ®Google Scholar
• Loven D, Hardoff R, Sever ZB, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004;67(1/2):221–226.
   PubMed Web of Science ®Google Scholar
• Hahn BM, Schrell UMH, Sauer R, et al. Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol. 2005;74(2):157–165.
   PubMed Web of Science ®Google Scholar
• Weston GJ, Martin AJ, Mufti GJ, et al. Hydroxyurea treatment of meningiomas: a pilot study. Skull Base Off J North Am Skull Base Soc Al. 2006;16(3):157–160.
   PubMedGoogle Scholar
• Kim M-S, Yu D-W, Jung Y-J, et al. Long-term follow-up result of hydroxyurea chemotherapy for recurrent meningiomas. J Korean Neurosurg Soc. 2012;52(6):517–522.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2012;107(2):315–321.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston SK. Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol. 2011;104(3):765–771.
   PubMed Web of Science ®Google Scholar
• Swinnen LJ, Renkin C, Rushing EJ, et al. Proceedings SNO, annual meeting of the society of neuro-oncology, 18–21 Nov 2010, Montreal, QC. ongoing clinical trials. Abstract OT-08: iv70. Neuro-Oncol. 2010;12(suppl4):iv69–iv78.
   Google Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004;62(7):1210–1212.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78(3):271–276.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996;84(5):733–736.
   PubMed Web of Science ®Google Scholar
• Markwalder T-M, Seiler RW, Zava DT. Antiestrogenic therapy of meningiomas–a pilot study. Surg Neurol. 1985;24(3):245–249.
   PubMedGoogle Scholar
• Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15(1):75–77.
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991;74(6):861–866.
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006;24(8):727–733.
   PubMed Web of Science ®Google Scholar
• Touat M, Lombardi G, Farina P, et al. Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486). Acta Neurochir (Wien). 2014;156(10):1831–1835.
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Weiss MH. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol. 1990;8(1):61–65.
   PubMed Web of Science ®Google Scholar
• Jääskeläinen J, Laasonen E, Kärkkäinen J, et al. Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases. Acta Neurochir (Wien). 1986;80(1–2):35–41.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69(10):969–973.
   PubMed Web of Science ®Google Scholar
• Johnson DR, Kimmel DW, Burch PA, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro-Oncol. 2011;13(5):530–535.
   PubMed Web of Science ®Google Scholar
• Simó M, Argyriou AA, Macià M, et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol. 2014;73(5):919–923.
   PubMed Web of Science ®Google Scholar
• Marincek N, Radojewski P, Dumont RA, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med Off Publ Soc Nucl Med. 2015;56(2):171–176.
   PubMed Web of Science ®Google Scholar
• Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40(2):271–275.
   PubMed Web of Science ®Google Scholar
• Muhr C, Gudjonsson O, Lilja A, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7(8):2269–2276.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;113(8):2146–2151.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. CNS Oncol. 2013;2(3):227–235.
   PubMedGoogle Scholar
• Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211–217.
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WKA, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncol. 2009;11(6):853–860.
   PubMed Web of Science ®Google Scholar
• Horak P, Wöhrer A, Hassler M, et al. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. J Neurooncol. 2012;109(2):323–330.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Norden AD, Desjardins A, et al. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012;106(2):409–415.
   PubMed Web of Science ®Google Scholar
• Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncol. 2015;17(1):116–121.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014;117(1):93–101.
   PubMed Web of Science ®Google Scholar
• Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63–70.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187–193.
   PubMed Web of Science ®Google Scholar
• Nunes FP, Merker VL, Jennings D, et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PloS One. 2013;8(3):e59941.
   PubMed Web of Science ®Google Scholar
• Alanin MC, Klausen C, Caye-Thomasen P, et al. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series. Int J Neurosci. 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Gupta V, Su YS, Samuelson CG, et al. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg. 2007;106(3):455–462.
   PubMed Web of Science ®Google Scholar
• Sioka C, Kyritsis AP. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol. 2009;92(1):1–6.
   PubMed Web of Science ®Google Scholar
• Rockhill J, Mrugala M, Chamberlain MC. Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus. 2007;23(4):E1.
   PubMedGoogle Scholar
• Barresi V, Alafaci C, Salpietro F, et al. Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep. 2008;20(3):485–492.
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Rankin C, Townsend J, et al. Phase II double-blind randomized placebo-controlled study of mifepristone (RU-486) for the treatment of unresectable meningioma. Proc Am Soc Clin Oncol. 2001;20:56a. abstract 222.
   Google Scholar
• Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(34):4093–4098.
   PubMed Web of Science ®Google Scholar
• Chamberlain M. What constitutes activity of systemic therapy in recurrent meningioma? Neurology. 2015;85:1090.
   PubMedGoogle Scholar
• Goldsmith B, McDermott MW. Meningioma. Neurosurg Clin N Am. 2006;17(2):111–120, vi.
   PubMed Web of Science ®Google Scholar
• Arena S, Barbieri F, Thellung S, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. 2004;66(1–2):155–166.
   PubMed Web of Science ®Google Scholar
• Schulz S, Pauli SU, Schulz S, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res Off J Am Assoc Cancer Res. 2000;6(5):1865–1874.
   PubMed Web of Science ®Google Scholar
• Gerster-Gilliéron K, Forrer F, Maecke H, et al. 90Y-DOTATOC as therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med Off Publ Soc Nucl Med. 2015;56(11):1748–1751.
   PubMed Web of Science ®Google Scholar
• Wen PY, Quant E, Drappatz J, et al. Medical therapies for meningiomas. J Neurooncol. 2010;99(3):365–378.
   PubMed Web of Science ®Google Scholar
• Johnson M, Toms S. Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol. 2005;64(12):1029–1036.
   PubMed Web of Science ®Google Scholar
• Simon M, Boström JP, Hartmann C. Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery. 2007;60(5):787–798. discussion 787–798.
   PubMed Web of Science ®Google Scholar
• Pietras K, Sjöblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3(5):439–443.
   PubMed Web of Science ®Google Scholar
• Black PM, Carroll R, Glowacka D, et al. Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg. 1994;81(3):388–393.
   PubMed Web of Science ®Google Scholar
• Maxwell M, Galanopoulos T, Hedley-Whyte ET, et al. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer J Int Cancer. 1990;46(1):16–21.
   PubMed Web of Science ®Google Scholar
• Nagashima G, Asai J, Suzuki R, et al. Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression. Brain Tumor Pathol. 2001;18(1):1–5.
   PubMedGoogle Scholar
• Yang SY, Xu GM. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci Off J Neurosurg Soc Australas. 2001;8(Suppl 1):49–53.
   Google Scholar
• Johnson MD, Woodard A, Kim P, et al. Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg. 2001;94(2):293–300.
   PubMed Web of Science ®Google Scholar
• Todo T, Adams EF, Fahlbusch R, et al. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg. 1996;84(5):852–858. discussion 858–859.
   PubMed Web of Science ®Google Scholar
• Mazza E, Brandes A, Zanon S, et al. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2016;77(1):115–120.
   PubMed Web of Science ®Google Scholar
• Nassehi D, Dyrbye H, Andresen M, et al. Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema. APMIS Acta Pathol Microbiol Immunol Scand. 2011;119(12):831–843.
   PubMed Web of Science ®Google Scholar
• Preusser M, Hassler M, Birner P, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol. 2012;31(09):352–360.
   PubMed Web of Science ®Google Scholar
• Boström JP, Seifert M, Greschus S, et al. Bevacizumab treatment in malignant meningioma with additional radiation necrosis. An MRI diffusion and perfusion case study. Strahlenther Onkol Organ Dtsch Röntgenges Al. 2014;190(4):416–421.
   PubMed Web of Science ®Google Scholar
• Ly KI, Hamilton SR, Rostomily RC, et al. Improvement in visual fields after treatment of intracranial meningioma with bevacizumab. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2015;35(4):382–386.
   Web of Science ®Google Scholar
• Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487–1495.
   PubMed Web of Science ®Google Scholar
• Grimm S, Kumthekar P, Chamberlain M, et al. Phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. Neuro-Oncol. 2015;17(suppl5):v130. (abstract MNGO-04).
   Google Scholar
• D’Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010;9(8):2157–2163.
   PubMed Web of Science ®Google Scholar
• Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer Oxf Engl 1990. 2001;37(1):97–105.
   PubMed Web of Science ®Google Scholar
• Minuzzo M, Marchini S, Broggini M, et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A. 2000;97(12):6780–6784.
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23(2):249–262.
   PubMed Web of Science ®Google Scholar
• Preusser M, Spiegl-Kreinecker S, Lötsch D, et al. Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer. 2012;118(20):5038–5049.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Cresta S, Maki RG, et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer Oxf Engl 1990. 2012;48(16):3036–3044.
   PubMed Web of Science ®Google Scholar
• Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8(7):595–602.
   PubMed Web of Science ®Google Scholar
• Carter NJ, Keam SJ. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs. 2010;70(3):335–376.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(19):3107–3114.
   PubMed Web of Science ®Google Scholar
• Pachow D, Andrae N, Kliese N, et al. mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(5):1180–1189.
   PubMed Web of Science ®Google Scholar
• Graillon T, Defilles C, Mohamed A, et al. Combined treatment by octreotide and everolimus: octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. J Neurooncol. 2015;124(1):33–43.
   PubMed Web of Science ®Google Scholar
• Koschny R, Boehm C, Sprick MR, et al. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex. J Neuropathol Exp Neurol. 2014;73(11):1034–1046.
   PubMed Web of Science ®Google Scholar
• Domingues P, González-Tablas M, Otero Á, et al. Genetic/molecular alterations of meningiomas and the signaling pathways targeted. Oncotarget. 2015;6(13):10671–10688.
   PubMed Web of Science ®Google Scholar
• Shah NR, Tancioni I, Ward KK, et al. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol. 2014;134(1):104–111.
   PubMed Web of Science ®Google Scholar
• Mordechai O, Postovsky S, Vlodavsky E, et al. Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature. Pediatr Hematol Oncol. 2015;32(3):207–211.
   PubMed Web of Science ®Google Scholar